Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ
CN Bio’s PhysioMimix® technology receives FDA recognition
FDA publication demonstrates advantages of PhysioMimix® in drug safety and metabolism applications, over standard techniques Represents the first
CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following
CN Bio to provide drug metabolism and safety toxicity testing services
Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell
CN Bio and Imperial College London Collaboration
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis. CN Bio’s Liver-on-Chip technology to define
CN Bio makes key senior appointments to support international commercial development
Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales Cambridge, UK, 05 August 2020: CN Bio, a leading
CN Bio and Cambridge University identify novel regulatory pathway driving NASH
Paper published in Nature Metabolism demonstrates novel pathway regulating the underlying mechanism of liver fibrosis
CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)
Investment will support commercial development in key markets, US and Europe Funding led by CITIC Securities Investment and supported by
NASH drug discovery service launched at AASLD
Leading bioengineering company CN Bio has launched a fee for service program providing Human Organ-on-Chip data to scientists studying non-alcoholic